NCT00909181 - Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence | Biotech Hunter

Enrollment

626

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

November 30, 2010

Conditions

Urge Urinary IncontinenceUrinary Frequency

Interventions

DRUG

Oxybutynin

"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"

DRUG

Placebo

"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"

Trial Locations (55)

11211

Brooklyn

12401

Kingston

12601

Poughkeepsie

13760

Endwell

14221

Williamsville

19004

Bala-Cynwyd

19446

Landsdale

21204

Towson

21401

Annapolis

23294

Richmond

27103

Winston-Salem

27518

Cary

27607

Raleigh

27609

Raleigh

28075

Harrisburg

28144

Salisbury

28209

Charlotte

28401

Wilmington

29464

Mt. Pleasant

29572

Myrtle Beach

29615

Greenville

30281

Stockbridge

30328

Sandy Springs

31904

Columbus

33024

Pembroke Pines

33161

North Miami

33414

Wellington

33607

Tampa

33710

St. Petersburg

34232

Sarasota

34625

New Port Richey

35233

Birmingham

37334

Fayetteville

44218

Wadsworth

48604

Saginaw

49503

Grand Rapids

50266

West Des Moines

57104

Sioux Falls

60201

Evanston

63017

Chesterfield

71106

Shreveport

72211

Little Rock

73008

Bethany

84604

Provo

89130

Las Vegas

90048

Los Angeles

92103

San Diego

92120

San Diego

92653

Laguna Hills

97330

Corvallis

98104

Seattle

99207

Spokane

06032

Farmington

06052

New Britain

02472

Watertown